Evidence map›Paper›PMID 41686644›Full record

ArticleSTAR protocols2026

Protocol for lentiviral engineering and multi-omic characterization of human kidney tubuloids.

Giulia Perticari, Maroussia M P Ganpat, Jarno Drost

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in STAR protocols, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Giulia PerticariPrincess Máxima Center for Pediatric Oncology, Oncode Institute, Heidelberglaan 25, Utrecht 3584 CS, the Netherlands.
Maroussia M P GanpatPrincess Máxima Center for Pediatric Oncology, Oncode Institute, Heidelberglaan 25, Utrecht 3584 CS, the Netherlands.
Jarno DrostPrincess Máxima Center for Pediatric Oncology, Oncode Institute, Heidelberglaan 25, Utrecht 3584 CS, the Netherlands; Utrecht University, Division Cell Biology, Metabolism & Cancer, Department Biomolecular Health Sciences, Faculty of Veterinary Medicine, Utrecht 3584 CL, the Netherlands. Electronic address: j.drost@prinsesmaximacentrum.nl.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Organoids derived from normal human tissue have proven to be effective preclinical models for studying tumor progression through the introduction of driver mutations. In this protocol, we outline techniques for disease modeling using organoids derived from healthy kidney tissue, also known as tubuloids. We provide step-by-step instructions for the establishment and passaging of tubuloids, lentiviral transduction, processing for histological analysis, and preparation for CUT&RUN and single-cell transcriptomic profiling. For complete details on the use and execution of this protocol, please refer to Ganpat et al.

Indexed as

Genetic EngineeringKidneyKidney TubulesLentivirusOrganoidsHumansMultiomicsCancerCell BiologyGenomicsOrganoidsSingle CellStem Cells

Identifiers

PMID41686644
PMCPMC12915182

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.